Electra Therapeutics, Inc. ETRA
Electra Therapeutics, Inc. (Nasdaq: ETRA) is a hematology drug developer. Its lead program, ipsoprubart (formerly ELA026), is in Phase 2 for secondary hemophagocytic lymphohistiocytosis (sHLH). Its next catalyst on record is ELA822: Phase 1 healthy-volunteer data (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ELA822 — Phase 1 healthy-volunteer data (H1 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ipsoprubart (SURPASS Phase 2/3 registrational) | sHLH | antibody | Phase 2 |
| ipsoprubart monotherapy Phase 1 | relapsed/refractory T/NK cell malignancies | antibody | Phase 1 |
| ELA822 (SIRPg-specific mAb) Phase 1 in healthy volunteers | T cell-mediated immune and inflammatory diseases | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.